Sesen Bio, Inc. (SESN) EPS Estimated At $-0.07

November 10, 2018 - By Ruchi Gupta

Analysts expect Sesen Bio, Inc. (NASDAQ:SESN) to report $-0.07 EPS on November, 19.They anticipate $0.30 EPS change or 81.08 % from last quarter’s $-0.37 EPS. After having $-0.16 EPS previously, Sesen Bio, Inc.’s analysts see -56.25 % EPS growth. The stock decreased 3.76% or $0.07 during the last trading session, reaching $1.79. About 1.35 million shares traded or 31.49% up from the average. Sesen Bio, Inc. (NASDAQ:SESN) has risen 54.17% since November 10, 2017 and is uptrending. It has outperformed by 38.55% the S&P500.

Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. The company has market cap of $137.85 million. It develops its products based on its Targeted Protein Therapeutics platform. It currently has negative earnings. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer.

Another recent and important Sesen Bio, Inc. (NASDAQ:SESN) news was published by Seekingalpha.com which published an article titled: “Portola Pharmaceuticals among healthcare gainers; Endo International tops losers” on November 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>